Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 21;8(1):e000579. doi: 10.1136/jitc-2020-000579

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Functional assessment of CTLA4 binding by ipilimumab released from Pickering emulsions using ethiodized oil and poly-lactic-co-glycolic acid nanoparticles (PEEP). (A) Design of competitive binding assay of ipilimumab and PEEP–ipilimumab on CTLA4-Ig transgenic cell line. PEEP–ipilimumab was collected after 21 days of release by the PEEP. Medium: non-treated cell; ipilimumab: addition of native ipilimumab and then Alexa Fluor 647 (AF647)-conjugated ipilimumab; PEEP–ipilimumab 21D: addition of release sample of ipilimumab at 21 days and then AF647-conjugated ipilimumab; IPIAF647: addition of AF647-conjugated ipilimumab. Median fluorescence intensity (MFI) of binding assay experiment is shown on bottom table. (B) Both ipilimumab and PEEP–ipilimumab induced a decrease of fluorescence suggesting effective binding to its ligand.